Mode
Text Size
Log in / Sign up

Sarcopenia in older patients with sepsis is associated with specific plasma metabolomic changes

Sarcopenia in older patients with sepsis is associated with specific plasma metabolomic changes
Photo by National Cancer Institute / Unsplash
Key Takeaway
Note the association between sarcopenia and specific metabolic pathway changes in older patients with sepsis.

This prospective observational cohort study evaluated 84 older patients with sepsis to examine the relationship between sarcopenia and plasma metabolomic changes. The study compared patients with sarcopenia to a non-sarcopenia group to identify differential metabolites and pathway enrichment.

Researchers identified 203 significantly differential metabolites, consisting of 71 upregulated and 132 downregulated metabolites. Pathway enrichment analysis indicated that these metabolites were primarily concentrated in steroid hormone synthesis, arachidonic acid metabolism, and valine, leucine, and isoleucine degradation. The results showed downregulated pathways related to muscle synthesis, such as branched-chain amino acid metabolism and steroid hormone metabolism, alongside upregulated pathways representing injury and the production of inflammatory mediators.

Safety and tolerability data were not reported. The study identified an association between the metabolic profile and sarcopenia in sepsis patients, but it did not establish causality. These metabolic changes may provide potential targets for the future development of early diagnostic biomarkers and targeted intervention strategies in this population.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundSarcopenia has a high incidence in older patients with sepsis and is closely associated with poor prognosis, but its metabolic characteristics under this specific stress state remain unclear. This study aims to reveal the specific plasma metabolomic changes related to sarcopenia in older patients with sepsis.MethodsA prospective observational cohort design was adopted, involving 84 older patients with sepsis, who were divided into a sarcopenia group (35 cases) and a non-sarcopenia group (49 cases). Fasting plasma samples were collected within 24 h, and untargeted metabolomic analysis was performed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) technology. Multivariate statistical methods such as principal component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) were used to screen differential metabolites, and KEGG pathway enrichment analysis was conducted.ResultsA total of 4,752 metabolites were identified, and 203 significantly differential metabolites were screened out (71 upregulated and 132 downregulated), indicating that the plasma metabolic profile of sarcopenic patients presents an “inhibitory” feature. The differential metabolites were mainly enriched in core pathways such as valine/leucine/isoleucine degradation, arachidonic acid metabolism, and steroid hormone synthesis. Specifically, metabolic pathways promoting muscle synthesis (such as steroid hormone and branched-chain amino acid metabolism) were generally downregulated, while pathways representing catabolism and injury (such as inflammatory mediator production) were significantly upregulated. Correlation analysis of differential metabolites revealed an interconnected metabolic disorder network.ConclusionThis study preliminarily reveals the unique plasma metabolic profile of elderly patients with sepsis complicated by sarcopenia, which is characterized by the impact on core pathways such as branched-chain amino acid degradation, steroid hormone synthesis inhibition, and arachidonic acid metabolism activation. These findings systematically depict the potential metabolic imbalance networks associated with this disease state, provide new clues for understanding its pathophysiological mechanisms, and offer an important theoretical basis and potential targets for the future development of early diagnostic biomarkers and targeted intervention strategies for this disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.